Dermtech Stock Net Income
DermTech fundamentals help investors to digest information that contributes to DermTech's financial success or failures. It also enables traders to predict the movement of DermTech Stock. The fundamental analysis module provides a way to measure DermTech's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to DermTech stock.
DermTech |
DermTech Company Net Income Analysis
DermTech's Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Current DermTech Net Income | (100.89 M) |
Most of DermTech's fundamental indicators, such as Net Income, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, DermTech is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
CompetitionBased on the recorded statements, DermTech reported net income of (100.89 Million). This is 129.56% lower than that of the Biotechnology sector and 158.28% lower than that of the Health Care industry. The net income for all United States stocks is 117.67% higher than that of the company.
DermTech Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses DermTech's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of DermTech could also be used in its relative valuation, which is a method of valuing DermTech by comparing valuation metrics of similar companies.DermTech is currently under evaluation in net income category among its peers.
DermTech Fundamentals
| Return On Equity | -1.22 | |||
| Return On Asset | -0.39 | |||
| Operating Margin | (5.33) % | |||
| Current Valuation | 15.43 M | |||
| Shares Outstanding | 34.96 M | |||
| Shares Owned By Insiders | 2.62 % | |||
| Shares Owned By Institutions | 18.09 % | |||
| Number Of Shares Shorted | 3.36 M | |||
| Price To Earning | (139.70) X | |||
| Price To Book | 0.02 X | |||
| Price To Sales | 0.21 X | |||
| Revenue | 15.3 M | |||
| Gross Profit | 647 K | |||
| EBITDA | (97.89 M) | |||
| Net Income | (100.89 M) | |||
| Cash And Equivalents | 173.79 M | |||
| Cash Per Share | 5.78 X | |||
| Total Debt | 54.39 M | |||
| Debt To Equity | 0.14 % | |||
| Current Ratio | 12.19 X | |||
| Book Value Per Share | 1.14 X | |||
| Cash Flow From Operations | (76.98 M) | |||
| Short Ratio | 2.64 X | |||
| Earnings Per Share | (2.65) X | |||
| Target Price | 1.5 | |||
| Number Of Employees | 206 | |||
| Beta | 2.42 | |||
| Market Capitalization | 3.29 M | |||
| Total Asset | 121.93 M | |||
| Retained Earnings | (423.94 M) | |||
| Working Capital | 48.3 M | |||
| Current Asset | 140.61 K | |||
| Current Liabilities | 446.54 K | |||
| Net Asset | 121.93 M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.
Other Consideration for investing in DermTech Stock
If you are still planning to invest in DermTech check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the DermTech's history and understand the potential risks before investing.
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. |